[go: up one dir, main page]

AU2001280804A1 - Aldosterone blocker therapy to prevent or treat inflammation-related disorders - Google Patents

Aldosterone blocker therapy to prevent or treat inflammation-related disorders

Info

Publication number
AU2001280804A1
AU2001280804A1 AU2001280804A AU8080401A AU2001280804A1 AU 2001280804 A1 AU2001280804 A1 AU 2001280804A1 AU 2001280804 A AU2001280804 A AU 2001280804A AU 8080401 A AU8080401 A AU 8080401A AU 2001280804 A1 AU2001280804 A1 AU 2001280804A1
Authority
AU
Australia
Prior art keywords
prevent
related disorders
treat inflammation
blocker therapy
aldosterone blocker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280804A
Inventor
Eileen R. Blasi
Ellen G. Mcmahon
Richardo Rocha
Marc D. Zack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU2001280804A1 publication Critical patent/AU2001280804A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41521,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001280804A 2000-07-27 2001-07-26 Aldosterone blocker therapy to prevent or treat inflammation-related disorders Abandoned AU2001280804A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22135800P 2000-07-27 2000-07-27
US60/221,358 2000-07-27
US26135201P 2001-01-12 2001-01-12
US60/261,352 2001-01-12
PCT/US2001/023520 WO2002009683A2 (en) 2000-07-27 2001-07-26 Aldosterone blocker therapy to prevent or treat inflammation-related disorders

Publications (1)

Publication Number Publication Date
AU2001280804A1 true AU2001280804A1 (en) 2002-02-13

Family

ID=26915708

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280804A Abandoned AU2001280804A1 (en) 2000-07-27 2001-07-26 Aldosterone blocker therapy to prevent or treat inflammation-related disorders

Country Status (6)

Country Link
US (1) US20030162759A1 (en)
EP (1) EP1368009A2 (en)
JP (1) JP2004518611A (en)
AU (1) AU2001280804A1 (en)
CA (1) CA2416152A1 (en)
WO (1) WO2002009683A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508174A (en) * 2002-01-25 2006-03-09 ファルマシア・コーポレーション Aldosterone blocker therapy to prevent or treat inflammation-related diseases
WO2003080069A1 (en) * 2002-03-18 2003-10-02 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
BR0313693A (en) * 2002-08-23 2007-08-14 Pharmacia Corp modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker (s)
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
EP1558265B1 (en) * 2002-11-05 2010-01-06 Bayer Schering Pharma Aktiengesellschaft Use of drospirenone for the treatment of hypertension
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
US8409815B2 (en) 2002-11-16 2013-04-02 Siemens Healthcare Diagnostics Products Gmbh sCD40L and placental growth factor (PLGF) used as a biochemical marker combination in cardiovascular diseases
US20050014732A1 (en) * 2003-03-14 2005-01-20 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-diabetic agent
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
US20070123498A1 (en) * 2003-10-17 2007-05-31 Shetty Suraj S Combination of organic compounds
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
CN101505795B (en) * 2006-07-03 2013-02-13 查尔斯·戴维·阿代尔 Compositions for modulating expression of cell adhesion molecules
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US20090089628A1 (en) * 2007-10-01 2009-04-02 Day Mark S File system error detection and recovery framework
AU2009306404B2 (en) 2008-10-24 2015-01-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Biomarkers of Mineralocorticoid Receptor activation
US20120058205A1 (en) * 2009-03-04 2012-03-08 Walter Howard Peschel Compositions and treatment regimes for reducing inflammation, end-organ injury, and/or systemic endotoxemia
DE102011015142A1 (en) * 2011-03-17 2012-09-20 Eberhard-Karls-Universität Tübingen Universitätsklinikum Agent for the prophylaxis and treatment of age-associated diseases and disorders and for extending the life

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (en) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-methylene-spirolactones, processes for their preparation and pharmaceuticals containing them
US5134150A (en) * 1985-12-12 1992-07-28 Smithkline Beecham Corporation Inhibition of the 5-lipoxygenase pathway
US5348729A (en) * 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
US5550124A (en) * 1991-12-10 1996-08-27 University Of Southern California Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
AU2385795A (en) * 1994-04-12 1995-10-30 Alza Corporation Screening methods for integumental inflammation modulating agents
AU4777896A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
JPH0971586A (en) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd New bicyclic condensed imidazole derivative
EP1920773B1 (en) * 1996-11-05 2011-01-05 The Children's Medical Center Corporation Thalidomide and dexamethasone for the treatment of tumors
WO1999058117A1 (en) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Use of compounds for reducing apoptosis
EP1077702A1 (en) * 1998-05-22 2001-02-28 The University Of British Columbia Peripheral benzodiazepine receptor ligands
WO2000010552A2 (en) * 1998-08-24 2000-03-02 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury
UA74141C2 (en) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Oral pharmaceutical compositions comprising micronized eplerenone (variants), method for its production and method for treating aldosterone-mediated states (variants)
ES2288487T3 (en) * 1999-11-09 2008-01-16 Pharmacia Corporation USE OF EPLERENONE FOR TREATMENT OF RESTENOSIS.
EP1282410A2 (en) * 2000-04-12 2003-02-12 Novartis AG Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects

Also Published As

Publication number Publication date
WO2002009683A2 (en) 2002-02-07
EP1368009A2 (en) 2003-12-10
JP2004518611A (en) 2004-06-24
WO2002009683A9 (en) 2003-06-12
US20030162759A1 (en) 2003-08-28
CA2416152A1 (en) 2002-02-07
WO2002009683A3 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
AU2001280804A1 (en) Aldosterone blocker therapy to prevent or treat inflammation-related disorders
AU2001257342A1 (en) Treatment well tiltmeter system
AU3920900A (en) Compounds and methods to treat cardiac failure and other disorders
AU2002223827A1 (en) Well treatment
AU2001282717A1 (en) Cancer treatment by combination therapy
AU2002210463A1 (en) Transdermal therapeutic system
AU2002210462A1 (en) Transdermal therapeutic system for treating restless-legs-syndrome
AU2001251011A1 (en) Treatments for immune-mediated ear disorders
AU7360000A (en) Methods and compositions for preventing and treating prostate disorders
AU7377200A (en) Combination therapy including camptothecin
AU2660099A (en) Readily absorbable phytosterols to treat hypercholesterrolemia
AU2001222215A1 (en) Lumbago treating girdle
AU2002249779A1 (en) Method to treat hemophilia
AU2002230888A1 (en) Methods and compositions to treat conditions associated with neovascularization
AU2002222240A1 (en) Nerve regeneration
AUPR074500A0 (en) Treatment of t cell disorders
AU2001227972A1 (en) Methods to treat alpha-1-antitrypsin deficiency
AU5042000A (en) Methods of treating proliferative disorders
AU2001229597A1 (en) Compositions and methods to treat neurodegenerative disorders
AU1449501A (en) Iontophoretic treatment system
AU2001294183A1 (en) Waste treatment equipment
PL373391A1 (en) Aldosterone blocker therapy to prevent or treat inflammation-related disorders
AU2080201A (en) Treatment of addiction disorders
AU2000231423A1 (en) Specific therapeutic composition for treating aids
AU2001261324A1 (en) Psoriasis treatment